NL2035196A - Lactobacillus fermentum and applications of lactobacillus fermentum in preparation for alleviating alcoholic-induced gastric injury - Google Patents
Lactobacillus fermentum and applications of lactobacillus fermentum in preparation for alleviating alcoholic-induced gastric injury Download PDFInfo
- Publication number
- NL2035196A NL2035196A NL2035196A NL2035196A NL2035196A NL 2035196 A NL2035196 A NL 2035196A NL 2035196 A NL2035196 A NL 2035196A NL 2035196 A NL2035196 A NL 2035196A NL 2035196 A NL2035196 A NL 2035196A
- Authority
- NL
- Netherlands
- Prior art keywords
- lactobacillus fermentum
- preparation
- insdseq
- insdqualifier
- insdfeature
- Prior art date
Links
- 241000186840 Lactobacillus fermentum Species 0.000 title claims abstract description 82
- 229940012969 lactobacillus fermentum Drugs 0.000 title claims abstract description 82
- 230000002496 gastric effect Effects 0.000 title claims abstract description 54
- 230000001476 alcoholic effect Effects 0.000 title claims abstract description 24
- 238000002360 preparation method Methods 0.000 title claims description 48
- 230000006378 damage Effects 0.000 title claims description 29
- 208000027418 Wounds and injury Diseases 0.000 title description 25
- 208000014674 injury Diseases 0.000 title description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 47
- 239000000203 mixture Substances 0.000 claims description 38
- 230000014509 gene expression Effects 0.000 claims description 33
- 230000000694 effects Effects 0.000 claims description 25
- 239000006041 probiotic Substances 0.000 claims description 19
- 235000018291 probiotics Nutrition 0.000 claims description 19
- 102100028452 Nitric oxide synthase, endothelial Human genes 0.000 claims description 18
- 101710111444 Nitric oxide synthase, brain Proteins 0.000 claims description 16
- 108010075520 Nitric Oxide Synthase Type III Proteins 0.000 claims description 15
- 102100022397 Nitric oxide synthase, brain Human genes 0.000 claims description 15
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 15
- 102000004889 Interleukin-6 Human genes 0.000 claims description 13
- 108090001005 Interleukin-6 Proteins 0.000 claims description 13
- 102100040247 Tumor necrosis factor Human genes 0.000 claims description 13
- 229940100601 interleukin-6 Drugs 0.000 claims description 13
- 108010037462 Cyclooxygenase 2 Proteins 0.000 claims description 12
- 230000002757 inflammatory effect Effects 0.000 claims description 8
- 230000028709 inflammatory response Effects 0.000 claims description 7
- 235000013325 dietary fiber Nutrition 0.000 claims description 5
- 238000000855 fermentation Methods 0.000 claims description 5
- 230000004151 fermentation Effects 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 239000000499 gel Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 239000006166 lysate Substances 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- 235000013406 prebiotics Nutrition 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 3
- 230000004792 oxidative damage Effects 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 2
- 238000009629 microbiological culture Methods 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 claims 2
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 claims 1
- 230000002906 microbiologic effect Effects 0.000 claims 1
- 210000001156 gastric mucosa Anatomy 0.000 abstract description 28
- 208000007107 Stomach Ulcer Diseases 0.000 abstract description 11
- 201000005917 gastric ulcer Diseases 0.000 abstract description 11
- 208000025865 Ulcer Diseases 0.000 abstract description 6
- 230000001154 acute effect Effects 0.000 abstract description 6
- 230000000740 bleeding effect Effects 0.000 abstract description 6
- 239000012530 fluid Substances 0.000 abstract description 4
- 231100000957 no side effect Toxicity 0.000 abstract description 3
- 230000036269 ulceration Effects 0.000 abstract description 3
- 230000000968 intestinal effect Effects 0.000 abstract description 2
- 244000005700 microbiome Species 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 43
- 210000001519 tissue Anatomy 0.000 description 36
- 108020004999 messenger RNA Proteins 0.000 description 22
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 15
- 235000019441 ethanol Nutrition 0.000 description 15
- 102000010907 Cyclooxygenase 2 Human genes 0.000 description 11
- 102000019197 Superoxide Dismutase Human genes 0.000 description 10
- 108010012715 Superoxide dismutase Proteins 0.000 description 10
- 239000003833 bile salt Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 9
- 229960003180 glutathione Drugs 0.000 description 9
- 239000001963 growth medium Substances 0.000 description 9
- 229940118019 malondialdehyde Drugs 0.000 description 9
- 230000006870 function Effects 0.000 description 8
- 210000004051 gastric juice Anatomy 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- -1 oxygen radicals Chemical class 0.000 description 8
- 230000000529 probiotic effect Effects 0.000 description 8
- 239000003963 antioxidant agent Substances 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 7
- 210000001035 gastrointestinal tract Anatomy 0.000 description 7
- 208000032843 Hemorrhage Diseases 0.000 description 6
- 230000003078 antioxidant effect Effects 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 238000003794 Gram staining Methods 0.000 description 5
- 241001325209 Nama Species 0.000 description 5
- 238000012408 PCR amplification Methods 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 4
- 230000021164 cell adhesion Effects 0.000 description 4
- 230000003628 erosive effect Effects 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 239000003390 Chinese drug Substances 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 102000003810 Interleukin-18 Human genes 0.000 description 3
- 108090000171 Interleukin-18 Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 101710090055 Nitric oxide synthase, endothelial Proteins 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000036542 oxidative stress Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 208000034158 bleeding Diseases 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000006059 cover glass Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000015784 hyperosmotic salinity response Effects 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229940069328 povidone Drugs 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- KEQXNNJHMWSZHK-UHFFFAOYSA-L 1,3,2,4$l^{2}-dioxathiaplumbetane 2,2-dioxide Chemical compound [Pb+2].[O-]S([O-])(=O)=O KEQXNNJHMWSZHK-UHFFFAOYSA-L 0.000 description 1
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 101000998969 Homo sapiens Inositol-3-phosphate synthase 1 Proteins 0.000 description 1
- 102100036881 Inositol-3-phosphate synthase 1 Human genes 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N Magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 230000002292 Radical scavenging effect Effects 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 108010091383 Xanthine dehydrogenase Proteins 0.000 description 1
- 102000005773 Xanthine dehydrogenase Human genes 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 208000028505 alcohol-related disease Diseases 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 238000005554 pickling Methods 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000012257 pre-denaturation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 235000020192 probiotic milk Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000011506 response to oxidative stress Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- GNBVPFITFYNRCN-UHFFFAOYSA-M sodium thioglycolate Chemical compound [Na+].[O-]C(=O)CS GNBVPFITFYNRCN-UHFFFAOYSA-M 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Mycology (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present application belongs to the technical field of microorganism applications, and specifically relates to an application of a lactobacillus fermentum TY—W08 in alleviating acute alcoholic-induced gastric ulcer. The lactobacillus fermentum is assigned with the accession number of CGIVICC No. 24629. The lactobacillus fermentum TY—W08 has desirable 10 gastrointestinal fluid tolerance and intestinal colonization capability, may significantly improve bleeding and ulceration of alcoholic-induced gastric mucosa and effectively improve alcoholic-induced gastric ulcer, and has no side effects and high safety. Fig. 4
Description
LACTOBACILLUS FERMENTUM AND APPLICATIONS OF LACTOBACILLUS FERMENTUM IN
PREPARATION FOR ALLEVIATING ALCOHOLIC-INDUCED GASTRIC INJURY
The present application belongs to the technical field of microorganism applications, and specifically, relates to a lactobacillus fermentum and applications of the lactobacillus fermentum in a preparation for alleviating alcoholic-induced gastric injury.
Wine culture has a long history in our country and is part of our culture and life, and plays an even more important role in today's business and social activities. However, functions of a plurality of systems throughout a human body may be affected after the intaking of alcohol, which is likely to cause alcohol-related diseases. For example, drinking alcohol may harm the gastric mucosa (gastric mucosa tissue covers the inner surface of the stomach and secretes mucus to protect the stomach), causing gastric injury or inflammation. In addition, the fat-soluble nature of ethanol is very likely to cause gastric injury, and the ethanol may be metabolized into acetaldehyde in the human body, which can directly attack the gastric mucosa.
The alcohol may stimulate microcirculatory blood vessels of the mucosa, causing contraction of the microcirculatory blood vessels; and inflammatory mediators and cytokines are generated after mucosal ischemia and hypoxia, neutrophil aggregation and infiltration are caused, and injury progression is aggravated and promoted. The alcohol also causes microcirculation disturbance, and the existence form of xanthine dehydrogenase is also affected after tissue ischemia and hypoxia, generating large amounts of oxygen radicals such as superoxide anion, hydrogen peroxide and hydroxyl radicals, thus causing oxidative stress. In addition, inflammatory response and oxidative stress response may promote each other, thereby aggravating the degree of tissue injury.
Currently, some probiotics have been shown to have good antioxidant and free radical scavenging capabilities and beneficial functions such as enhancing the human immune; and the probiotics have no side effects and high safety. Therefore, it is necessary to discover a probiotic that may alleviate alcoholic-induced gastric injury.
In view of the above problems, one of the objectives of the present application is to provide a lactobacillus fermentum TY-WO8 that is separated from Qula in Halama 1st Village,
Angu, Hongyuan County, Aba Tibetan and Qiang Autonomous Prefecture, Sichuan Province.
The lactobacillus fermentum may alleviate oxidative stress in the human body by improving the antioxidant capacity of the human body, so as to reduce inflammatory response of the human body, thereby alleviating alcoholic-induced gastric injury.
In order to achieve the above purpose, the present application may use the following technical solutions.
One aspect of the present application provides a lactobacillus fermentum. The lactobacillus fermentum is deposited with the China General Microbiological Culture
Collection Center (CGMCC) and is assigned with the accession number of CGMCC No. 24629.
Another aspect of the present application provides a composition. The composition may include one or a combination of a plurality of the following substances: (a) the lactobacillus fermentum; (b) lysate of the lactobacillus fermentum; {c) a culture of the lactobacillus fermentum; and (d} a fermentation broth of the lactobacillus fermentum.
Still another aspect of the present application provides a preparation. The preparation includes the lactobacillus fermentum or the composition, and a carrier. The carrier is a medicinal carrier or an edible carrier.
Still another aspect of the present application provides applications of the lactobacillus fermentum or the composition in preparation of preparations used for alleviating alcoholic-induced gastric injury.
The collection information of the lactobacillus fermentum in the present application includes the following. The lactobacillus fermentum is deposited with the CGMCC at No. 3,
Yard 1, BeiChen West Road, Chaoyang District, Beijing on April 1, 2022 and is assigned with the accession number of CGMCC No0.24629, with the classification name being lactobacilius fermentum.
The beneficial effects of the present application are as follows. The lactobacillus fermentum has desirable gastrointestinal fluid tolerance and intestinal colonization capability, may significantly improve bleeding and ulceration of alcoholic-induced gastric mucosa and effectively improve alcoholic-induced gastric ulcer, and has no side effects and high safety.
Fig. 1 shows colonial morphology of TY-WO8.
Fig. 2 shows a gram staining result of TY-WO8.
Fig. 3 is a cell adhesion map of TY-WO8.
Fig. 4 is an appearance observation diagram of gastric tissue of mice.
Fig. 5 shows gastric mucosa injury indexes of mice.
Fig. 6 shows the impact of TY-WO08 on the content of Glutathione (GSH) in gastric tissue of mice.
Fig. 7 shows the impact of TY-WO8 on the content of Malondialdehyde (MDA) in gastric tissue of mice.
Fig. 8 shows the impact of TY-WO8 on the activity of Superoxide Dismutase (SOD) in gastric tissue of mice.
Fig. 9 shows the impact of TY-W08 on mRNA relative expression of TNF-a in gastric tissue of mice.
Fig. 10 shows the impact of TY-WO8 on mRNA relative expression of IL-6 in gastric tissue of mice.
Fig. 11 shows the impact of TY-W08 on mRNA relative expression of {L-1Bin gastric tissue of mice.
Fig. 12 shows the impact of TY-WO8 on mRNA relative expression of COX-2 in gastric tissue of mice.
Fig. 13 shows the impact of TY-WO8 on mRNA relative expression of eNOS in gastric tissue of mice.
Fig. 14 shows the impact of TY-WO8 on mRNA relative expression of nNOS in gastric tissue of mice.
Fig. 15 shows the impact of TY-WO8 on mRNA relative expression of iNOS in gastric tissue of mice.
In the drawings: "*" represents that there is a statistical difference {p < 0.05) between two groups; "**" represents that there is a statistical difference {p < 0.01) between two groups; "***" represents that there is a statistical difference (p < 0.001) between two groups; and "****" represents that there is a statistical difference (p < 0.0001} between two groups.
The embodiments are given to better describe the present application, but the content of the present application is not limited only to the embodiments given. Therefore, non-essential improvements and adjustments to the embodiments made by a person skilled in the art in accordance with the content of the above present application still fall within the scope of protection of the present application.
The terms used herein are only intended to describe specific embodiments and are not intended to limit the present disclosure. Expressions in the singular form include those in the plural form unless the expressions have a distinctly different meaning in the context. As used herein, it is to be understood that terms such as "include", "have", "contain", and the like are intended to indicate the presence of features, figures, operations, components, parts, elements, materials, or combinations. The terms of the present application are disclosed in the specification and are not intended to exclude the possibility that one or more other features, figures, operations, components, parts, elements, materials, or combinations thereof may exist or may be added. As used here, "/" may be interpreted as "and" or "or", as appropriate,
A lactobacillus fermentum in the present application is also called a lactobacillus fermentum TY-WO8 or TY-WO8.
In the present application, the term "preparation" does not only refer to a pharmaceutical preparation for medicinal purposes, but also includes an edible food preparation or a health care product preparation.
An embodiment of the present application provides a lactobacilius fermentum TY-WOB8.
The lactobacillus fermentum is deposited with the CGMCC and is assigned with the accession number of CGMCC No. 24629. it is to be noted that, the lactobacillus fermentum is derived from Qula in Halama 1st
Village, Angu, Hongyuan County, Aba Tibetan and Qiang Autonomous Prefecture, Sichuan
Province. After being detected by means of gram staining results, the lactobacillus fermentum is found to be in a rod-like shape, and is determined as gram-positive bacteria (G*). In addition, by means of PCR amplification of a 165rDNA sequence, the 16SrDNA sequence is detected to include a sequence shown as SEQIDNO.1, and by means of homology analysis, it indicates that the strain is the lactobacillus fermentum. In addition, the lactobacillus fermentum has strong gastric juice tolerance and bile salt tolerance; the survival rate of the lactobacillus fermentum in gastric juice may reach 98.66%; and the growth efficiency of the lactobacillus fermentum in bile salt may reach 28.45%. The number of TY-WO08 adhered by 100 cells is 256, and it indicates that the lactobacillus fermentum has desirable digestive tract resistance and good intestinal tract colonization capabilities.
Another embodiment of the present application provides a composition. The composition includes one or a combination of a plurality of the following substances: (a) the lactobacillus fermentum; (b) lysate of the lactobacillus fermentum; {c} a culture of the lactobacillus fermentum; and (d) a fermentation broth of the lactobacillus fermentum. it is to be noted that, in the composition, as described above, the lactobacillus fermentum TY-WO08 has desirable digestive tract resistance and good intestinal tract colonization capabilities, and may be prepared into an edible or medicinal composition. In addition, when the lactobacillus fermentum TY-WO8 is prepared into the composition, the lactobacillus fermentum may achieve an effect by being directly introduced into the composition in the form of viable bacteria, may achieve an effect by being introduced into the 5 composition in the form of inactivated bacteria after inactivation by means of the existing technology, may achieve an effect by introducing the lysate of the lactobacillus fermentum into the composition, may achieve an effect by introducing products such as proteins, peptides, secretions or metabolites obtained from the culture of the lactobacillus fermentum into the composition, or may achieve an effect by introducing the fermentation broth from the fermentation of the lactobacillus fermentum into the composition. In a specific use process, different forms of the lactobacillus fermentum may be selected for the preparation of the composition according to specific requirements.
In some specific embodiments, the composition may further include one or a combination of probiotics, prebiotics, dietary fiber and traditional Chinese drugs. it is to be noted that, the lactobacillus fermentum TY-WO8 and different forms thereof may also be used in combination with one or the combination of probiotics, dietary fiber and a pharmacologically active compound. For example, the lactobacillus fermentum TY-W08 may be used in combination with bacillus subtilis, bifidobacterium or lactobacillus, so as to cause the composition to simultaneously have the effects of the lactobacillus fermentum TY-WO08 and other probiotics. For another example, the lactobacillus fermentum TY-WO8 may be used in combination with the prebiotics, and the prebiotics may provide an energy source for the lactobacillus fermentum TY-WO8, such that the effect of the lactobacillus fermentum TY-W08 is improved. For another example, the lactobacillus fermentum TY-WO8 may be used in combination with the dietary fiber, and the dietary fiber may assist in colonization of the lactobacillus fermentum TY-WO8, such that the effect of the lactobacillus fermentum TY-WO8 is improved. For another example, the lactobacillus fermentum TY-W08 may also be used in combination with the traditional Chinese drugs to form the composition, such that the effects of the lactobacillus fermentum TY-WO8 and the traditional Chinese drugs are simultaneously achieved.
Still another embodiment of the present application provides a preparation. The preparation includes the lactobacillus fermentum or the composition, and a carrier. The carrier is a medicinal carrier or an edible carrier.
It is to be noted that, drugs or edible food or health care products may be prepared by adding the medicinal carrier or the edible carrier to the composition including the lactobacillus fermentum TY-WO8 and different forms thereof. The medicinal carrier or the edible carrier is known in the art and may be selected according to the dosage form as needed.
For example, the preparation of tablets mainly uses a diluent {such as starch, dextrin, sucrose or sugar), an absorbent (such as calcium sulfate, calcium hydrogen phosphate or light magnesium oxide), an adhesive {such as povidone, syrup or hydroxypropyl methylcellulose), a wetting agent (such as water), or a disintegrating agent (such as dry starch, sodium hydroxymethyl starch or cross-linked povidone). For example, the preparation of the liquid preparation mainly uses a bulking agent, a suspending agent, an emulsifying agent, a colorant, or the like.
In some specific embodiments, the preparation is tablets, pills, capsules, powder, gel, granules or a liquid preparation. It is to be noted that, solid dosage forms such as the tablets, the pills, the granules or the capsules may be product forms such as probiotic tablets, probiotic sugar pills, probiotic powder or probiotic capsules. The liquid preparation may be a product form such as a probiotic beverage. The gel may be product forms such as probiotic jelly, probiotic milk foam or solidified yogurt.
Still another aspect of the present application provides applications of the lactobacillus fermentum or the composition in preparation of preparations used for alleviating alcoholic-induced gastric injury.
In some specific embodiments, the applications include applications of one or a combination of a plurality of the following: {a} an application of the lactobacillus fermentum or the composition in preparation of preparations used for alleviating oxidative damage to alcoholic-induced gastric tissue; {b) an application of the lactobacilius fermentum or the composition in preparation of preparations used for alleviating inflammatory response of alcoholic-induced gastric tissue; and {c) an application of the lactobacillus fermentum or the composition in preparation of preparations used for improving the expression level of endothelial Nitric Oxide Synthase (eNOS) and/or neuronal NOS (nNOS) in gastric tissue and/or reducing the expression level of induced NOS (iNOS).
In some specific embodiments, the application (a) includes an application of the lactobacillus fermentum or the composition in preparation of preparations used for improving the activity of SOD and/or the content of GSH in the alcoholic-induced gastric tissue, and/or reducing the content of MDA in the alcoholic-induced gastric tissue; and the application (b) includes an application of the lactobacillus fermentum or the composition in preparation of preparations used for reducing the expression level of an inflammatory factor Tumor Necrosis
Factor a (TNF-a) and/or Leukin-1B (L-18) and/or Interleukin-6 (IL-6) and/or Cyclooxygenase-2 (COX-2) in the alcoholic-induced gastric tissue. it is to be noted that, the gastric mucosa generates large amounts of oxygen radicals under the stimulation of ethanol; the oxygen radicals may cause lipid peroxidation in the gastric mucosa or mucosal cells at both the overall and cellular levels, so as to generate lipid peroxide such as the MDA, resulting in gastric mucosa injury caused by gastric mucosa blood flow disorder. The SOD and the GSH are the most important antioxidants against free radicals in the human body, may directly eliminate the free radicals, block the chain reaction of the free radicals, and have the effect of repairing cells. Heavy drinking may cause a significant decrease in SOD activity, resulting in weakened oxygen radical scavenging and causing damage to the human body. The lactobacillus fermentum TY-WO8 in the present application may significantly increase the activity of the SOD having an antioxidant function and the content of the GSH in the gastric tissue in the human body, and reduce the content of the lipid peroxide
MDA. it is further to be noted that, the ethanol may activate the immune system of the human body to affect the level of proinflammatory factors, including TNF-a and IL-1B. As an important cytokine having various functions, the TNF-a is closely related to the activation of other inflammatory factors {such as IL-1B and IL-6), and is involved in the development of inflammatory diseases. The activation of the IL-18 and the IL-6 may further promote the expression of the TNF-a, aggravating an inflammatory response. The TNF-a is one of the most potent inflammatory factors, such that the TNF-a is usually used as an index for determining the degree of inflammation. The COX-2 is an important inflammatory factor; and gastric injury may be significantly alleviated by inhibiting the degree of inflammation in gastric injury, such that the effect of inhibiting gastric inflammation may be achieved by controlling the expression of the COX-2 in the gastric tissue. The lactobacillus fermentum TY-WO8 in the present application may significantly reduce mRNA expression levels of an inflammatory factors such as Tumor Necrosis Factor a (TNF-a), Interleukin-1B (IL-1B), Interleukin-6 (IL-6) and
Cyclooxygenase-2 {COX-2).
It is further to be noted that, NOS in the gastric mucosa is divided into two categories; one category is constitutive NOS {cNOS, including eNOS and nNOS), and one category is iNOS.
Less NO is catalyzed by the cNOS, and plays a role in protecting the gastric mucosa to a certain extent. In addition, through research, it is found that the occurrence of gastric ulcer is related to excessive inhibition of the eNOS and the nNOS. After appropriate stimulation by endotoxin, the iNOS of an inducible form is generated. Under a physiological condition, the eNOS and the nNOS continuously synthesize the NO, which plays an important role in regulating a gastric tissue function. The iNOS is not expressed in a normal state; and the iNOS is heavily activated after the gastric tissue is damaged, further aggravating gastric injury. During the alleviation of the gastric ulcer, the content of the eNOS and the nNOS is increased, and a positive effect may be effectively achieved by reducing the content of the iNOS. The lactobacillus fermentum
TY-WO08 in the present application may significantly increase the mRNA expression levels of the eNOS and the nNOS, and significantly reduce the mRNA expression level of the iNOS.
In order to make objectives, technical solutions, and advantages of the present application clearer, the preferred embodiments of the present application will be described in detail below with reference to the drawings.
Embodiment 1: Separation, purification and identification of TY-W08 (1) Experimental material
Qula in Halama 1st Village, Anqu, Hongyuan County, Aba Tibetan and Qiang Autonomous
Prefecture, Sichuan Province: the Qula was collected by using a sterile spoon, and was put into a 15 mL sterile capped centrifuge tube containing a proper amount of sterile calcium carbonate and soluble starch; and the tube is screwed up, and then refrigerated and transported back to a laboratory. (2) Separation and purification of the TY-W08 10-fold gradient dilution was performed on the retrieved sample, so as to successively obtain diluent with dilution degrees of 107, 102, 10%, 10%, 10°, 10% and 107; 200 ut of the diluent with proper dilution degrees (103, 10%, 105 and 10%) was coated on an MRS solid culture medium, and the culture medium was inverted and cultured for 48h at 37°C; and after culture is finished, colonial morphology on an MRS plate was observed, single colonies with different morphology were selected, a streak plate method was adopted to separate strains, and the above steps were repeated until purified strains were obtained. The colonial morphology was observed, and morphological observation was performed by means of gram staining.
The colonial morphology of the purified strains was shown in Fig. 1. The colonies were consistent in morphology, moist and smooth in surface, medium in size, neat in edge, hemispherical in shape, and milk white in color.
The cell morphology of the purified strains after gram staining was shown in Fig. 2 (grey processing was performed in Fig. 2, and an original drawing was purple). Purple cell morphology with a rod-like shape was observed under a microscope, which accorded with the characteristics of the lactobacillus, such that the strains were determined as gram-positive bacteria (G*). (3) PCR amplification of 16S rDNA sequence
PCR amplification was performed by using a 25 uL of a reaction system, including 1 uL of a template, 1 uL of an upstream primer (10 uM), 1 uL of a downstream primer (10 pM), and 12.5 ul of 2xTag PCR Master Mix, and making up to 25 ub with sterile ultrapure water. Primer sequences included an upstream primer sequence AGAGTTTGATCCTGGCTCAG (SEQIDNO.2) and a downstream primer sequence TACGACTTAACCCCAATCGC (SEQIDNO.3). PCR amplification conditions included: performing pre-denaturation at 94°C for 5 min, performing denaturation at 94°C for 30 s, performing annealing at 55°C for 30 s, and performing extension at 72°C for 1 min, where there was a total of 35 cycles; and performing end extension at 72°C for 10 min. After sequence amplification, Sangon Biotech {Shanghai) Co., Ltd.
Was entrusted to sequence qualified PCR amplification products, and the obtained sequence was shown as SEQIDNo.1; and searching and similarity comparison were performed in
GeneBank by using BLAST(http://www.ncbi.nim.nih.gov/BLAST). Results showed that the strain in the present application is the lactobacillus fermentum.
Embodiment 2 Measurement of gastric juice tolerance and cell adhesion capability of
TY-W08 (1) Experimental material
A lactobacillus fermentum TY-WO8: separated from the Qula in Halama 1st Village, Anqu,
Hongyuan County in Sichuan Province, deposited with the CGMCC and is assigned with the accession number of CGMCC No. 24629. (2) Measurement of the TY-WO8 tolerant to artificial gastric juice with pH being 3.0 10 mi of a culture solution that has been well activated was taken, and was centrifuged at 4000r/min for 10 min, so as to collect bacterial precipitation, and the bacterial precipitation was resuspended in isochoric sterile saline to prepare bacterial suspension; 1 ml of the bacterial suspension and 9 ml of artificial gastric juice {0.2%NaCl and 0.35% pepsin being 1:10000, pH being adjusted to be 3 by using 1mol/L of HCI, and filtration sterilization being performed for later use} were mixed, well agitated and placed in a constant temperature oscillator to culture for 3h at 37°C and 100r/min; and sampling was performed at Oh and 3h, respectively, and viable counts were measured respectively by using a pour plate method.
3h viable count/(CFU/mL J+ survival rate 4 — we 100
Oh viable count/{CFLU/mL)<
Before the probiotics entered the human intestinal tract to exert functions, the probiotics needed to pass through the stomach (generally, the pH value of gastric juice is about 3.0} and stayed for about 3h, but the strongly acidic stomach environment was not conducive to the 3 survival of the probiotics. Therefore, the viability of the probiotics in simulated gastric juice is crucial. From the above experimental results, it showed that when being cultured for 3h under the acidic condition of pH=3.0, the survival rate of the TY-WO8 is 98.66%, such that the
TY-WO08 has very strong viability. (3) Measurement of TY-WO8 tolerant to 0.3% bile salt 10 The culture solution that has been well activated was taken, and inoculated in MRS-THIO culture media respectively containing 0.0 and 0.3% bile salt (0.2% sodium mercaptoacetate being added to an MRS liquid culture medium); and after well mixing, the culture media were placed in the constant temperature oscillator to culture for 24h at 37°C and 100r/min, and growth efficiency was calculated. 0.3% bile salt containing culture medium ODeso0m- growth efficiency/%« … blank control QDsoeow wx 1H) 0.0% bile salt containing culture medium ODeovs--
B blank-control-QDeo0s
The survived probiotics were in contact with the bile salt in the small intestine after passing through the stomach, and the mass concentration of the bile salt in the human body fluctuated within the range of 0.03%-0.3%. From the above experimental results, it showed that the growth efficiency of the TY-WO8 in the bile salt with the concentration being 0.3% is 28.45%, such that the TY-WO08 has desirable bile salt tolerance. (4) Measurement of cell adhesion capability of TY-W08
HT-29 cells were resuspended by using a McCoy's 5A culture medium, and the number of cells was adjusted to 2x10° cell/mL; a 6-well culture plate was placed into cover glass which has been subjected to acid pickling and sterilization, and 2 mL of cell suspension was respectively added to each well; and culture was performed overnight at 37°C and 5% CO..
After the cells were attached to the wall of the cover glass, sterile PBS was used for washing for 3 times; the bacterial suspension was added {the TY-WO08 being resuspended by using the
McCoy's 5A culture medium {without adding penicillin-streptomycin and fetal bovine serum),
until the concentration of bacterial fluid was 108CFU/mL); incubation was performed for 2h, and then the culture solution was discarded; the sterile PBS was used for washing for 6 times; and 2 mL of methanol was added in each well, and was cured for 1h at room temperature for gram staining. The total number, that is, an adhesion value, of TY-W08 adhered by 100 cells was recorded under the microscope {20 views being randomly selected).
The TY-WO8 could achieve the probiotic function on the host only by being adhered to human intestinal epithelial cells and finally colonized on the intestinal epithelium. Generally, if the number of strains adhered to 100 cells is less than 40, it indicates that the strain has no adhesion capability; if the number of strains adhered to 100 cells is between 41 and 100, it indicates that the strain is general in adhesion capability; and if the number of strains adhered to 100 cells exceeds 100, it indicates that the strain is strong in adhesion capability. The adhesion capability of the TY-W08 was evaluated by using the HT-29 cells to simulate human intestinal epithelial cells. An experimental result was shown in Fig. 3, the number of the
TY-WO08 adhered by 100 cells is 256, such that the TY-W08 has strong cell adhesion capabilities, indicating that the TY-WO8 has strong intestinal tract colonization capabilities.
Embodiment 3 Effect of TY-WO08 on alleviating acute alcoholic-induced gastric ulcer (1) Experimental material
A lactobacillus fermentum TY-WO08: separated from the Qula in Halama 1st Village, Anqu,
Hongyuan County in Sichuan Province, deposited with the CGMCC and is assigned with the accession number of CGMCC No. 24629.
Acute alcoholic-induced gastric ulcer model in mice: before a formal experiment, the mice were adaptively fed for a week. After an adaptive phase ended, the mice were randomly grouped into 3 groups (n=8) according to weights, which are Group Control, Group EtOH, and
Group TY-WO8. The Group TY-WO8 was intra-gastrically administered with 1.0x10° CFU/kg of
TY-WO08 bacterial fluid daily for 28 days, continuously; and Group Blank and the Group EtOH were intra-gastrically administered with equivalent amount of normal saline. At Day 29, the mice in each group were fasted for 12 hours before model building; and then the mice in the
Group EtOH and the Group TY-WO08 were intra-gastrically administered with an ethanol solution {12ml/kg) with volume fraction of 50% at one time, so as to prepare an acute alcoholic-induced gastric ulcer model in the mice; and the mice in the Group Blank is given equal amount of normal saline. The mice were sacrificed after 10 hours of intragastric administration with the ethanol solution. The gastric tissue was taken and cut along greater curvature of the stomach; stomach contents were washed; and the gastric mucosa was unfolded, and was photographed by a digital camera. (2) Measurement of gastric mucosa injury indexes of the mice
Situations of the gastric mucosa of the mice in each group were shown in Fig. 4. The gastric mucosa of the mice in the Group Control was compact in structure, normal in color and smooth in surface, and had no bleeding points and erosion. Compared with the Group Control, the gastric mucosa of the mice in the Group EtOH was seen with visible patchy tissue erosion, and obvious bleeding, tissue congestion and edema, and was reddish in color, The degree of injury of the gastric mucosa of the mice in the Group TY-WO8 is equivalent as that of the gastric mucosa of the mice in Group Control when being observed with naked eyes; and no obvious erosion or bleeding was seen, only tissue congestion was more pronounced than that in the gastric tissue of the Group Control, and the degree of injury was significantly less than that of the Group EtOH.
Gastric mucosa injury of the mice was observed with naked eyes, and the index of gastric mucosa injury was measured by using a straight scale (the index of gastric mucosa injury was calculated by using a Guth method: every three punctate ulcers {of which width of hemorrhagic erosive dots or mucosa defect is less than 1 mm) were recorded as 1 point; stripe hemorrhage: the maximum length diameter of the ulcer and the maximum width diameter perpendicular to the maximum length diameter were measured, and the product of the maximum length diameter and the maximum width diameter was an ulcer index; and the one with the width being 1 mm was 1 point per millimeter length, the one with the width being 2 mm was 2 points per millimeter length, the one with the width being 3 mm was 3 points per millimeter length, and so on). Measurement results of the mice in each group were shown in
Fig. 5. The ethanol (EtOH) obviously increased the index of gastric mucosa injury of the mice.
Compared with the Group EtOH, the index of gastric mucosa injury in the Group TY-W08 was significantly reduced {p<0.0001), and the results showed that the TY-W08 could effectively alleviate the gastric mucosa injury of the mice caused by alcohol. (3) Measurement of an oxidation index of gastric tissue in the mice
A BCA kit (which was purchased from Shanghai Beyotime Biotechnology Co., Ltd} was used to measure protein concentration of gastric tissue homogenate of the mice.
Kits (which were all purchased from Nanjing Jiancheng Bioengineering Institute) were respectively used to measure GSH content, MDA content and SOD activity of the gastric tissue in the mice.
Experimental results were shown in Fig. 6, Fig. 7 and Fig. 8. Compared with the Group
Control, the SOD activity (p<0.001) and the GSH content (p<0.001) of the mice in the Group
EtOH were significantly reduced, and the MDA content was significantly increased {p<0.0001}; and after TY-WO8 intervention, the SOD activity (p<0.0001), the GSH content (p<0.001} and the MDA content (p<0.0001) of the mice could all be recovered to normal levels. The results showed that the TY-WO8 had the effect of alleviating oxidative damage caused by the ethanol. (4) Measurement of mRNA expression level of gastric tissue in the mice
A TRizol reagent was used to extract the total RNA of the gastric tissue, and the total RNA was subjected to reverse transcription to cDNA by using a reverse transcription kit; and the
MRNA expression levels of target genes TNF-a, IL-6, IL-1B, COX-2, eNOS, nNOS and iNOS were detected by means of a fluorescence quantitative PCR instrument. A primer sequence was shown in Table 1, and the mRNA relative expression levels of the target genes were calculated by using a 224% method.
Table 1 Primer sequence
TNF-a-F CCTGTAGCCCACGTCGTAG(SEQIDNO.4)
TNF-a-R GGGAGTAGACAAGGTACAACCC(SEQIDNO.5)
IL-6-F TAGTCCTTCCTACCCCAATTTCC(SEQIDNO.6)
IL-6-R TTGGTCCTTAGCCACTCCTTC{SEQIDNO. 7)
IL-1B-F GAAATGCCACCTTTTGACAGTG(SEQIDNO.8)
IL-1B-R TGGATGCTCTCATCAGGACAG(SEQIDNO.9)
COX-2-F TTAAAATGAGATTGTCCGAA(SEQIDNO.10)
COX-2-R AGATCACCTCTGCCTGAGTA(SEQIDNO.11) eNOS-F GGAGAGGCTGCATGACATTG(SEQIDNO.12) eNOS-R GGTAGAGCCATAGTGGAATGAC(SEQIDNO.13) nNOS-F GAATACCAGCCTGATCCATGGAA(SEQIDNO.14) nNOS-R TCCTCCAGGAGGGTGTCCACCGCATG(SEQIDNO.15) iNOS-F AGAGAGATCGGGTTCACA(SEQIDNO.16)
INOS-R CACAGAACTGAGGGTACAÍSEQIDNO. 17)
GAPDH-F TGACCTCAACTACATGGTCTACA(SEQIDNO.18)
GAPDH-R CTTCCCATTCTCGGCCTTG(SEQIDNO.19)
The mRNA relative expression levels of the TNF-a, IL-6, IL-18 and COX-2 of the gastric tissue in the mice were respectively shown in Fig. 9, Fig. 10, Fig. 11 and Fig. 12. Compared with the Group EtOH, the mRNA relative expression levels of the TNF-a (p<0.05), IL-18 {(p<0.05), IL-6 (p<0.05) and COX-2 {p<0.05} of the gastric tissue in the mice in the Group
TY-WO08 were all significantly reduced. The results showed that the TY-W08 may alleviate an inflammatory response, and reduce the damage of the alcohol to the gastric mucosa, thereby achieving the effect of protecting the gastric mucosa.
The mRNA relative expression levels of the eNOS, nNOS and iNOS of the gastric tissue in the mice were shown in Fig. 13, Fig. 14 and Fig. 15. Compared with Group Control, the expression levels of the eNOS {p<0.05) and the nNOS (p<0.05) of the mice in the Group EtOH were obviously reduced, and the mRNA relative expression level of the INOS (p<0.05) was obviously increased; and after TY-WO08 intervention, the mRNA relative expression levels of the eNOS (p<0.05) and the nNOS (p<0.05)} of the mice were significantly increased, and the mRNA relative expression level of the iNOS (p<0.05) was significantly reduced. The results showed that the TY-WO8 had a certain protection effect on the gastric ulcer caused by the ethanol, and was related to the antioxidant capability of the TY-W08 in the human body.
To sum up, the lactobacilius fermentum TY-WO8 in the present application has desirable gastric juice tolerance and good intestinal tract colonization capabilities. The TY-WO8 can improve acute alcoholic-induced gastric mucosa bleeding and ulceration of the mice, and may significantly increase the activity of the SOD having an antioxidant function and the content of the GSH in the gastric tissue, reduce the content of the lipid peroxide MDA, reduce the mRNA expression levels of the inflammatory factors TNF-a, L-1B, IL-6 and COX-2, increase the mRNA expression levels of the eNOS and the nNOS, and reduce the mRNA expression level of the iNOS. Therefore, the lactobacillus fermentum TY-WO8 achieves the purpose of alleviating acute alcoholic-induced gastric ulcer by means of cooperation of simultaneously improving the antioxidant capabilities of the mice, alleviating oxidative stress of the human body and reducing the inflammatory response of the human body, and potential interventions are provided for the prevention of the alcoholic-induced gastric ulcer. it is finally to be noted that, the above embodiments are merely for describing and not intended to limit the technical solutions of the present application. Although the present application is described in detail with reference to the preferred embodiments, those of ordinary skill in the art should understand that the technical solutions of the present application can be modified or equivalently replaced without departing from the purpose and scope of the technical solutions of the present application, and shall all fall within the scope defined by the claims of the present application.
1 <?xml version="i 0" encoding=rUTE-8" 72 7 <!DOCTYPE ST26SequenceListing PUBLIC "-//WIPO//DTD Sequence Listing 1.3//EN" "3T26Sequencelisting V1 3.dtd"> 3 <STZ6Sequenceldsting AtcdVersion="vi 3% {1lleName="T¥-20R2-11-24~1. aml? zoitwareName=
PHIRG Sequence" zoftwarsVersion="2, 3,09 produnhioniate=t2083-06-28"> 4 <ApplicapniFileRefersnce»TY-xuliebiao</AppliicantFileReferaenca> <ApplicaniNeme lencuagelcds="zh'"vChongqing Tianyou Dairy Co. Ltd.</ApplicantName> iS <ApplicanilNamelatin>Chongging Tianyou Dairy Co. Ltd.</ApplicantNameLatin> 7 <inventorNeme languagelcde="zh">Zhang Feng /InveniorName> a <“inventorNamelLetin>Zhang Feng</InventorNamelLatin» 3 <inventionTitie languagenode="zh">Lactobacillus Fermentum and Applications of
Lactobacillus Fermentum in Preparation for Alleviating Alcoholic-Induced Gastric
Injury /inventionTitle»> if <SeguenceTotalQuantity>l19</SeguenceTotelQuantity> ii <SequenceData semencelDNumber=Nij> 12 <INSDSeq> ij «<INSDSeg iength>1437</INSD3eqg length» 14 <INSDSeq moltype>DNA</INSDSeg moltyper
Lj <INSDSeq division>PAT</INSD3eg division» iE <INSDSeq featura-table>
Lj <INSDFeatura>
ES <IN3DFeature key>source</IN3DFeature key>
LG <IN3DFeature location>1..1437</INSDFeature locations» 240 <INSDFeature guals> 2 <INSDQualiifisr>
ZE <INSDQualifier name»mol type“/INSDCualifier name» 23 <INSDQualifier value>genomic DNA</InNSDRualifier value» 24 </INSDOualifiers aL <INSDQuaizifler ia="giN>
ZE <INSDQualifier namerorganism</INSDQualifier name>
LT <INSDQualifier valuerLactobacillus fermentans </INSDgualifier value» zó </INSDQualifiers» a </INSDFeaturs quals> </INSDFeature> 31 </INSD3eq feature-table>
Ss <INSDSeq sequencer ggctggectcctaaaaggttaccccaccgactttgggtgttacaaactctcatggtgtgacgggcggtgtgtaca aggcccgggaacgtattcaccgeggcatgctgatcegcgattactagcgattcegacttegtgcaggcgagttg cagcctgcagtccgaactgagaacggttttaagagatttgettgccctecgegagttegecgactecgttgtacegt ccattgtagcacgtgtgtagcccaggtcataaggggcatgatgatctgacgtegtccccaccttcctceggttt gtcaccggcagtctcactagagtgcccaacttaatgctggcaactagtaacaagggttgegctecgttgcgggac ttaacccaacatctcacgacacgagctgacgacgaccatgcaccacctgtcattgegttcccgaaggaaacgcc ctatctctagggttggcgcaagatgtcaagacctggtaaggttettecgegtagcttegaattaaaccacatgct ccaccgcttgtgegggcccecgtcaattcctttgagtttcaaccttgeggtecgtactccccaggcggagtgett aatgegttagctcecggcactgaagggcggaaaccctccaacacctagcactcatecgtttacggcatggactacc agggtatctaatcctgttegctacccatgetttegagtctcagegtcagttgcagaccaggtagcecgecttege cactggtgttettccatatatctacgcattccaccgctacacatggagttccactaccctcttctgcactcaag ttatccagtttecgatgcacttctceggttaagccgaaggctttcacatcagacttagaaaaccgcctgcactec tetttacgcccaataaatccggataacgecttgccacctacgtattaccgeggctgctggcacgtagttagcegt gactttetggttaaataccgtcaacgtatgaacagttactctcatacgtgttettetttaacaacagagcttta cgagccgaaacccttcttcactcacgeggtgttgectccatcaggcttgegcccattgtggaagattccctactg ctgcectceccgtaggagtatgggcecgtgtetcagtcccattgtggcecgatcagtctectcaactcggctatgcate atcgccttggtaggcecgttaccccaccaacaagctaatgcaccgcaggtccatccagaagtgatagcgagaagc catcttttaagcgttgttcatgcgaacaacgttgttatgeggtattagcatctgtttccaaatgttgtccceceg cttctgggcaggttacctacgtgttactcacccgtcegccactegttggecgaccaaaatcaatcaggtgcaagc accatcaatcaattgggccaacgegttegac:/INSDSeq sequence» </INSDSeg> 34 </Sequencelatal
BL <Seduencelsta seqvenceliNumber="d*> 36 <INSDSeq> 37 <INSDSeg length>20</INSD5eq length» 3G <INSDSeg moltype>DNA</INSDSeg moltype> 3 <INSDSeq division PAT</INSDSeq division>
AU <INSDSeq feature-tahle> u 41 <IN3DFeature> 4% “INSDFeature keyrsource</INSDFeaturs key» 43 “INSDFeature location>l..20</IN3DFeature location 44 <INSDFeature guals> <INSDQualifier> 46 <INSDQualifier name>mol type</INSDRualifier name>
47 <INSDOualifier valusrother DNA</INIDOualifier valuer 48 </INSDQualifier> u
A <INSDQualifler id="gg9>
LG <INSDQualifizr name>organism</INSDOualifier named
Sl <INSDQualifisr valus>synthetic construct </INSDGualifier value» 52 </INSDDualliier> 32 </INSDFeature quals>
Sd </TNEDFeature> 55 “/INSDSeg feature-table»
De “INSDSeg sequencs>agagtttgatcctggctcag</INSDSeq sequence» 57 </INSDSeg> he </Seguencebata> 5g <Sequencedata sagiencelDlumber="37> “0 <INSDSeg> ad <IN3DSeq length»20</INSDSeq lengith> a2 <INSDSeg moltype>DNA</INSDSeq moltype> a3 <INSDSeq division>PAT</INSD3eg division» a4 <INSDSeg feature-table>
Gh <INSDFeature> a8 <IN3DFeature hey>source</IN3DFeature hey» 7 <INSDFeature location>1..20</INSDFeature Location» en <INSDFeature guals> a <INSDQualiifisr>
GG <IN3DQualifier name>mol type</INSDQualifier name>
TL <INSDQualifier valuelother DNA“/INSDQualifier values
FE </INSDOualifiers
EN <INSDQuaizifier ia=tglilv>
Fd <INSDQualifier namerorganism</INSDCualiifier name>
TE <INSDQualifier valuersynthetic construct </INSDgualifier value» 7E </INSDQualifiers» 77 </INSDFeature quals> 78 </INSDFeatures 7 <{INSDSeg feature-takle>
GU <INSDSeq sequence>tacgacttaacceccaatege</INSDSeq sequsnce> 41 </INSDSeg>
G3 </SaequenceData a3 <SedgquenceData seguanceliNumbaer="47>
Gd CINSDSeg> a5 <INSDSeq length>19</INSDSeq length
Sa <INsSDfeq moltyperDNA</INSDSeg moitype> 27 <INSDSeq divigion>PAT</INSDSeg division» ga <INSDSeqg featurertabie» 8a <INSDFeatures <IN3DFeature keyrsource</IN3DFeature key» il <INSDFeature location>1..19</INSDFeature iccation> 32 <INSDFeature guals> 33 <INSDQualifier>
G4 <INSDgualifier name mol type</INSDQualifier nama> 95 <INSDQualiifier valuevother DNA</INSDQualifier value» zE </INSDGuaiifien> 37 <INSDQualifier 1d4=TgR2%>
SG <IN3DQualifier namevorganism</INSDQualifier name>
GG <INSDQualifler valuessynthetic construct </INSDRualifier values 100 </INSDCualifiern
LOL </INSDFeature quals»
TOE </INSDFeature»
LOS </INSDSeu feature-table> 104 <INSDSeq sequence»eetgtagcccacgtegtag:/INSDSeg sequence 105 </INSDSeg>
LOE </Sequencebatad>
LOT <Sequencebata zsegvencellNvumbec="5*z> ids <INSDSeqg>
Li <INSDSeq length>22</INSDSeq length>
LLG <INSDSeq moliype>DNA</INEDIag moliypa> 11d <INSDSeq division»PAT</INIDSzqg division>
LE <INSDSeq feature-table> lij <INSDFeature>
Lid “INSDFeature keyrsource</INSDFeaturs key»
Lis <INSDFeature location>l..22</IN3DFeature location»
Lie <INSDFeature cquals> u
LLT <INSDOuelijler»>
Lis <INSDQualifizr name>mol type</INSDoualifier named
Ti: <INSDQvalifier valus>other DNA</INSDQualifiern value>
LEG </INSDDualliier>
LEL <INSDQualiiler id="gg3r> 122 <INSDQualifier nams>organism</INSDRualifier named
LEZ <INSDQualiflisr valus>synthetic construct </INBDCualifier value» 12d </INSDDOualifier»> 125 </INSDFeature quals> 128 </INSDFeature»> 127 </INBDSeqg feature-table> ize <IN3DSeq =zequence>gggagtagacaaggtacaacce</IN3DSeqg sequenced 128 </INSDBeg> 130 </SeguenceData> 13% <SeguenceData seauencelDNumber="&N> 132 <INSDSeg> 133 <INSDSeq lengih>23</INSDSeq lengch> 134 <INSDSeq moltype>DNA</INSDSeg moltyper 13% <IN3DSeq divisilon>PAT</INSDEeq division> 138 <INSDSeq feabure-table>
TRE <INSDFeaturse> 138 <IN3DFeature key>source</IN3DFeature key>
L3G <INSDFeature location>l..23</IN3SDFeature location»
LAG <INSDFeature guals> u
LAD <INSDQualifier>
Laz <INSDQualifier namedmol type</INSDCualiifier name>
LAS <INSDQualifier valuerother DNA</INSDQualifier values
Láá </INSDQualifiers»
HE <INSDQualifiler id=tgddd>
LAE <INSDQualifier namerorganism</INSDQualifier name> 147 <INSDQualifisr valus>synthetic construct </INSDQualifier valued 148 </INSDOQualifiers
Tal </INSDFeaturs quals> 159 </TNEDFeature> ini </INSDEeq feaature-table> 152 <INSDSeq sequence>tagteetteetaccccaatttee:/INSISeq ssguenca> 152 </INSDSaeg> 154 </Seguencebata> 155 “SequenceData seaguencelDNumber="7F7> 15a <INSDSeq> 157 <INSDSeq length>21</INSDSeq length> ihe <INSDSeg moltype>DNA</INSDSeq moltype> 188 <INSDSeq division>PAT</INSDSeg division» ien <INSDSeq feature-table> 1A <INSDPeature> 182 <IN3DFeature hey>source</IN3DFeature hey» 183 <INSDFeature location>l..21</INSDFeature location» 164 <INSDFeature guals> 18s <INSDQualifiec> ied <IN3DQualifier name>mol type“/INSIQualifier name> iej <INSDoualiiler valuevother DNA“ /INSDQvalifier value 1a8 </INSDCualifiern ies <INSDQualifier id=Vg25nx>
LEG <INSDQualifier namerorganism</INSDCualiifier name>
LL <INSDQualifier value»synthetic construct </INSDQualifier valued
EE </INSDOualifiers
LS </INSDFeature dquals> 174 </INSDFeature>
HN </INSDSeg feature-table> iG <INSDSeg sequencerttggtecttagecactectte</iNSDSeq sequencer 177 </INSDSag>
LS </SequenceData>
BARE. <HGegquenceData seguanceTLNugbhao="8">
Lol AINSDSeq 181 <INSDSeq length>22</INSDSeq Lengih> 182 <INSDSeq moltyperDNA</INSDSag moliypex
LTE <INSDSeq division PAT</INSDSeq division>
Lod <INSDSeq feature-table> u
Lon <INSDFeature»
LOE “INSDFeature keyrsource</INSDFeaturs key»
Lan “INSDFeature location>l..22</IN3DFeature location 188 <INSDFealure guals>
Las <INSDQualifier>
Ze <INSDQualifier nams>»mol1 type</INSDRualifier named ee <INSDQualifler valussother DNA</INSDQualifier value> 102 </INSDDOualifier»> 153 <INSDOualifier id="g28%> ijd <INsSDQualifiler name>organism</INSDQualifier named 135 <INSDQualifier value>synthetic construct </INSDQualifier value» 188 </INSDOualifier> 187 </INSDFeature guals> 139 </INSDFeatura> 18% </TN3DSag feature-tablex 200 <INSDSeg seguence>rgaaatgccaccttttgacagtg/INSDSag sequence 2071 </INSDSeg> u 202 </SegvenceDalar 207% <Seqgquencebata zagquencallDNumber=ngns 204 <INSDSeq> 20% <INSDSeg Lengih>21</INSDSeq length» 206 <INSDSeg moltype>DNA</INSDSeq moltype> 247 <INSDSeg division>»PAT</INSDSeg division»
ZUS <INSDSeq feature-tables u
ZOU <INSDFeature>
ZEG <INSD¥eature key>source</INSDFeature key»
Zi <INSDFeature location>l..21</IN3DFeature location» die <INSDFeature quals> u
ALS <INBDQualiifier>
Sh <INSDQualifier namermol type</INSDQualifier name>
PAA] <INSDQualifier valus>other DNA</INSDQualifisr valuer
ZL </INSDOQualifiers u “17d <INSDQualifler id="gs7>
SLE <INSDQualifizr name>organism</INSDOualifier named
Zij <INSDgualifier valus>synthetic construct </INSDGualifier value»
Ei) </INSDOualLliier»
Zed </INSDFeature quals> 222 </INSDFeature»> zal “/INSDSeg feature-table» zz “INSDSeg sequencs>tggatgctetcatcaggacag:/INSDSeq sequenced 228 </INSD3Sec> 228 </SeguenceData> 227 <Sequencedata saquencellumber="10"> 228 <INSDSeg> 228 <IN3DSeq length»20</INSDSeq lengith> 230 <INSDSeq moltype>DNA</INSDSeg moltyper 23 <INSDSeq division>PAT</INSD3eg division» 232 <INSDSeg feature-table> 233 <INSDFeature> 2734 <IN3DFeature key>source</IN3DFeature key> 23% <IN3DFeature location>1..20</INSDFeature Location» 236 <INSDFeature guals> 2 <INSDQualiifisr> 233 <INSDQualifier namedmol type</INSDCualiifier name> 23% <INSDQualifier valuelother DNA“/INSDQualifier values 240 </INSDOualifiers
ZAL <INSDQuaizifier ia="gl89>
ZAL <INSDQualifier namerorganism</INSDQualifier name>
EAS <INSDQualifier valuersynthetic construct </INSDgualifier value»
ZÂAÂ </INSDQualifiers»
Aas </TNSDFeaturs quals>
AAG </INSDFaatures> u wan <{INSDSeg feature-takle>
AAG “INSDSeq sequencerttaaaatgagattgtccgaa“/INSDSeq sequsnce> 2A </INSDSaeg> £50 </SaequenceData nl <Sequencebata segvencelbNumbec="1ljx>
PA <INSDSag>
PAIN <INSDSeq length>20</INSDSeqy length» ald <INSDSeq moliype>DNA</INEDIag moliypa>
Ass <INSDSeq division»PAT</INIDSzqg division> £58 <INSDSeq feature-tablex £57 <INSDFeature> 258 “INSDFeature keyrsource</INSDFeaturs key» £53 “INSDFeature location>l..20</IN3DFeature location? 250 <INSDFeature guals> aL <INSDOQualifier>
Zal <INsSDQualifiler name>mol type</INSDQualifier named al <INSDQualifier value>other DNA</INSDQualifier value»
Jad </INSDOualifier> 255 <INSDQualifier ld="gR®">
En <iNsSDQualifier namerorganism</INSDQualifier name> 2a <INSDQualifier value>synthetic construct </INSDQualifier value»
DEA </INSDQualifier> 288 </INSDFeature quals> 250 </TNSDFeatura>
ZL </INSDSeg feature-tabla>
ZE <INSDSeyq sequenceragatcacctetgectgagta</INIDSaeq sequence 275 </INSDSeg> u 274 </Seqguencelatal>
Zj <SeduencelDeta secqvencsliNumber="ig!» 27E <“INSDSeq> <INSDSeq length>20</INSLSeq length 29a <INSDSeq molitype>DNA</INSDSeq moltype»> 2 <INSDSeq division PAT</INSDSeq division>
ZOU <INSDSeq feature-tahle> u el <INSDFeature>
ZOE <INSDFeature keyrsource</INSDFeature key>
PATI <INSDFeatvure location>l..20</IN3DFeature locations
PRE: <INSDFeature quals> IJ
Zes <INSDOuelijler»>
ZES <INSDQualifizr name>mol type</INSDoualifier named a <INSDQualifler valussother DNA</INSDQualifier value>
ZEE </INSDOualLliier»
Zin <INSDQualiiler id="g39%> ii) <INSDQualifier nams>organism</INSDRualifier named
Zal <INSDQualifier value>synthetic construct </INBDCualifier value» ze </INSDDOualifier»> za “/INSDFearure quals> 234 </INSDFeatura> 235 </INBDSeqg feature-table> 238 <IN3DSeq =zequence>ggagaggctgecatgacattg</IiN3DSeg sequence» 257 </INSDBeg> 288 </SegvenceDalar 238 <SeguenceData seauencelDNumber="ijN> 200 <INSDSeq>
GEL <INSDSeq lengih>22</INSDSeq lengch> <IN3DSeq moltype>DNA</INSDSeq moltype> 3073 <IN3DSeq divisilon>PAT</INSDEeq division> 304 <INSDSeq feabure-table> 30% <“INSDFeacure> 306 <INSD¥eature key>source</INSDFeature key» 307 <INSDFeature location>l..22</IN3SDFeature location» 303 <INSDFeature guals> u
BOG <INSDQualifier>
SLE <INSDQualifier namermol type</INSDQualifier name>
IL <INSDQualifier valuerother DNA</INSDQualifier values
Zil </INSDQualifiers»
SLS <iNSDQvuelifier ia="gSlx> sLá <INSDQualifizr namerorganism</INSDQualifier name>
SLS <INSDQualifisr valus>synthetic construct </INSDGualifier value» 418 </INSDOQualifiers
Si </INSDFeature quals> sim </TNEDFeature>
SLS </INSDSeq Zeature-table>
IE <INSDSeq sequencevggtagagccatagtggaatgac-“/INSDSeq sequences
SEL </INSDSag>
SAE <{SeguenceDela>
SED <sSequenceDeta sequence lUNumhzr="14">
RYE CINSDSeg> sen <INSDSeq length>23</INSDSeq Lengih>
En <INSDSeq moltyperDNA</INSDSag moliypex
SE <INSDSeq division»>PAT</INSDSeg division» 329 <INSDSeqg featurertabie» 523 <INSDFPeature> 324 <INSDFeature keyrsource</INSDFeature key> 321 <INSDFeature location>»l..23</IiNSDFeature location» 222 <INSDFeature guals> 232 <INSDQualifier> 234 <iNsSDQualifier name>mol type“/INSDQualifier name> 235 <INSDQualifier value>other DNA</IN3DQualifier value» 226 </INSDGuaiifien> 237 <INSDQualifier 1d4="gl2%> 238 <INSDgualifier name>organism</INSDQualifier nama> 238 <INSDQualiiler valuersynthetic construct </INSDRualifier values 340 </INSDCualifiern 340 </INSDFzature duals» 345 </INSDFealurex
GAS </INSDSeu feature-table> 44 <INSDSeq sequencergaataccagectgatccatggaa</INSDSeg sequences 14% </INSDSeq> u 346 </Sequencelatal 347 <Sequencebata seguenasiliNombhar="189s 4G <INSDSeqg>
Fh <INSDSeg length>26</INSD5eq length»
FLU <INSDSeg moltype>DNA</INSDSeg moltype>
SLE <INSDSeq division»PAT</INIDSzqg division>
SLE <INSDSeq feature-table>
SLS <INSDFeature»
Sid “INSDFeature keyrsource</INSDFeaturs key» 355 “INSDFeature location>l..26</IN3DFeature location? 358 <INSDFealure guals> 57 <INSDQualifier>
LE <INSDQualifier nama>mol type</INSDRualifier named 358 <INSDQualifier value>other DNA</INSDQualifier value»
SA </INSDDOualifier»>
Sal <INSDOualifier id="g33%> 482 <INsSDQualifiler name>organism</INSDQualifier named
San <INSDQualifier value>synthetic construct </INSDQualifier value» 263 </INSDOualifier> 285 </INSDFeature guals> 288 </TNSDFeatura> 267 </INSDSeag feature-table>
Ian <INSDSeg gequencerteetccaggagggtgtccaccgcatg:/INSDSeg saguencea 26e </INSDSeg> IJ 3G </Beguencelata
SE <Seqguencebata sequencelDNumber="i&nx
SEE <INSDSeq> 33 <INSDSeg lengith>18</INSDSeq length»
IVA <INSDSeq molitype>DNA</INSDSeq moltype»>
IL <INSDSeg division>»PAT</INSDSeg division»
IEG <INSDSeq feature-table> u 3 <INSDFeature>
Gig <INSDFeature keyrsource</INSDFeature key>
Ra <INSDFeature location>l..18</IN3DFeature location»
IHU <INSDFeature quals> u
BEL <INBDQualiifier> sal <INSDQualifizr name>mol type</INSDoualifier named
Sol <INSDQualifier valus>other DNA</INSDQualifisr valuer sad </INSDOQualifiers u sos <INSDQualifler id="g34> 388 <INSDQualifier nams>organism</INSDRualifier named
Snij <INSDgualifier valus>synthetic construct
</INSDQualifier value» 168 </INSDQualifier> so </TNSDFeaturs quals> sel </INSDFaatures> u
Sei <{INSDSeg feature-takle> 302 <INSDSeq segquenceragagagatcgggttcaca</INESDSay sequence»
REICH </INSDSaeg>
RIERS </SaequenceData 305 <SegquenceDalta seguanceliNunbaer="17%> 256 <INSDSeqg> 307 <INSDSeq length>18</INSDSeq length> 339 <INsSDfeq moltyperDNA</INSDSeg moitype> 523 <INSDSeq divigion>PAT</INSDSeg division» 400 <INSDSeq feature-tablex 401 <INSDFeature> 402 <IN3DFeature keyrsource</IN3DFeature key» 4072 <INSDFeature locationrl..18</INSDFeature location> 404 <INSDFeature guals> 40% SINSDOualifiar> 40a <INSDgualifier name mol type</INSDQualifier nama> 4407 <INSDQualiifier valuevother DNA</INSDQualifier value» 308 </INSDGualifier:
JOS <INSDQualifier id="g35nx>
JLG <IN3DQualifier namevorganism</INSDQualifier name>
JL <INSDQualifler valuessynthetic construct </INSDQualifier valued
Alk </INSDQGualifier»
ALS </INSDFeature quals» 414 </INSDFeature»
A15 </INSDSeq Zeature-table> 414 <INSDSeg sequencercacagaactgagggtaca</INSDSeq sequenced 417 </INSDSeg>
Als </SequenceDala>
Ain <sSequenceDeta sequence lUNumhzr="18">
AED AINSDSeq dal <INSDSeq length>23</INSDSeqy lengtub> dz <INSDSeq mltype>DNA</INSDSeg moliypa> £432 <INSDSeq division»>PAT</INSDSeg division» dad <INSDSeq featurertablex £450 <INSDFeature>
AEG “INSDFeature keyrsource</INSDFeaturs key» 427 <INSDFeature location>»l..23</IiNSDFeature location» 429 <INSDFeature guals> 409 <INSDOQualifier> 420 <INsSDQualifiler name>mol type</INSDQualifier named 453 <INSDQualifier value>other DNA</IN3DQualifier value» 422 </INSDQualifier> 437 <INSDOualifier 1d=Vgl38"> 454d <iNsSDQualifier namerorganism</INSDQualifier name> 435 <INSDQualiiler valuersynthetic construct </INSDQualifier value» 436 </INSDQualifier> 437 </INSDFeature quals> 335 </INSDFealurex 339 </INSDSeg feature-tabla> 440 <INSDSeyg sequence>tgacectecaactacatggtetaca</INSDSag sequence dal </INSDSeg> IJ 44% </Sequencelatal 4473 <SeduencelDeta seguencelilNunbhar=vr189> 444 <INSDSeg> 44% <INSDSeq length>19</INSLSeq length 444 <INSDSeg moltype>DNA</INSDSeg moltype> 447 <INSDSeq division PAT</INSDSeq division> 44 <INSDSeq feature-tahle> u dát <INSDFeature>
G50 “INSDFeature keyrsource</INSDFeaturs key»
ALL <INSDFeatvure location>l..19</IN3DFeature locations
ALE <INSDFeature quals> IJ 453 <IN3DQualifier> 454 <INSDQualifier nama>mol type</INSDRualifier named 455 <INSDQualifler valussother DNA</INSDQualifier value>
ARE </INSDOualifiers 457 <INSDQualifler id="g37> 458 <INSDQualifizr name>organism</INSDOualifier named 457 <INSDQualifisr valus>synthetic construct </INSDQualifier value» 460 </INSDDualliier>
ASL </INSDFeature quals> 4672 </INSDFeaturex> £632 </INSDEeq feaature-table> ind <INSDSeq zegquence>ettcccatteteggcecttg</INSD3eq sequence» 455 </INSDSeg> 488 </Seguencebata> 487 </&T253eguencelisting> 489
Claims (9)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310011362.XA CN118291299A (en) | 2023-01-05 | 2023-01-05 | Lactobacillus fermentum and application thereof in preparation for relieving alcoholic gastric injury |
Publications (2)
Publication Number | Publication Date |
---|---|
NL2035196A true NL2035196A (en) | 2023-07-27 |
NL2035196B1 NL2035196B1 (en) | 2023-11-24 |
Family
ID=87378615
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NL2035196A NL2035196B1 (en) | 2023-01-05 | 2023-06-28 | Lactobacillus fermentum and applications of lactobacillus fermentum in preparation for alleviating alcoholic-induced gastric injury |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN118291299A (en) |
NL (1) | NL2035196B1 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106381278B (en) * | 2016-09-08 | 2019-05-10 | 济南康多宝生物技术有限公司 | A kind of lactobacillus preparation and its application in gastric ulcer treatment |
CN115029273A (en) * | 2022-06-22 | 2022-09-09 | 重庆市天友乳业股份有限公司 | Lactobacillus fermentum TY-G03 and application thereof |
-
2023
- 2023-01-05 CN CN202310011362.XA patent/CN118291299A/en active Pending
- 2023-06-28 NL NL2035196A patent/NL2035196B1/en active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106381278B (en) * | 2016-09-08 | 2019-05-10 | 济南康多宝生物技术有限公司 | A kind of lactobacillus preparation and its application in gastric ulcer treatment |
CN115029273A (en) * | 2022-06-22 | 2022-09-09 | 重庆市天友乳业股份有限公司 | Lactobacillus fermentum TY-G03 and application thereof |
Non-Patent Citations (2)
Title |
---|
SUO HUAYI ET AL: "Lactobacillus fermentum Suo Attenuates HCl/Ethanol Induced Gastric Injury in Mice through Its Antioxidant Effects", NUTRIENTS, vol. 8, no. 3, 10 March 2016 (2016-03-10), pages 155, XP093095949, DOI: 10.3390/nu8030155 * |
WANG RANRAN ET AL: "Pretreatment with Lactobacillus fermentum XY18 Relieves Gastric Injury Induced by HCl/Ethanol in Mice via Antioxidant and Anti-Inflammatory Mechanisms", DRUG DESIGN, DEVELOPMENT AND THERAPY, vol. Volume 14, 30 December 2020 (2020-12-30), pages 5721 - 5734, XP093008098, Retrieved from the Internet <URL:https://www.dovepress.com/getfile.php?fileID=65232> DOI: 10.2147/DDDT.S280429 * |
Also Published As
Publication number | Publication date |
---|---|
NL2035196B1 (en) | 2023-11-24 |
CN118291299A (en) | 2024-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113906129A (en) | Ackermanella muciniphila EB-AMDK19 strain and application thereof | |
CN108641988B (en) | Lactobacillus plantarum NA136 and application thereof in relieving non-alcoholic fatty liver disease | |
US11141444B2 (en) | Lactobacillus crispatus KBL693 strain and use thereof | |
WO2022110726A1 (en) | Application of lactobacillus paracasei subsp. paracasei k56 in improving intestinal bacterial infection resistance and intestinal immunity | |
WO2022148138A1 (en) | Lactobacillus crispatus capable of preventing and/or treating cervical squamous carcinoma | |
CN107299065A (en) | A kind of Lactobacillus plantarum and its application for preparing vagina antibacterial medicines | |
CN115948292B (en) | Lactobacillus reuteri strain A21041 with anti-inflammatory and antioxidant functions and application thereof | |
CN114317353A (en) | Lactobacillus plantarum ZJUFYJ7 and application thereof | |
CN110613738B (en) | Lactobacillus reuteri composition capable of relieving rheumatoid arthritis | |
WO2015101208A1 (en) | Vitamin d and antibacterial uses of composition thereof | |
WO2024146605A1 (en) | Lactobacillus plantarum and use thereof | |
CN112760247A (en) | Lactobacillus rhamnosus for preventing and/or treating diseases caused by genital tract flora disorder and/or bone loss | |
Wang et al. | Promotive effects of sesamin on proliferation and adhesion of intestinal probiotics and its mechanism of action | |
WO2012103785A1 (en) | Lactobacillus salivarius and method for preparing metabolite thereof, composition of lactobacillus salivarius and metabolite thereof and use of the composition | |
WO2024146604A1 (en) | Lactobacillus crispatus and use thereof | |
NL2035196B1 (en) | Lactobacillus fermentum and applications of lactobacillus fermentum in preparation for alleviating alcoholic-induced gastric injury | |
CN117701462A (en) | Anti-infection lactobacillus crispatus capable of promoting vaginal sIgA and IgG expression and metagen thereof both orally and externally | |
CN117625443A (en) | Lactobacillus gasseri for improving female private health and skin aging, and composition thereof | |
CN115612652B (en) | Lactobacillus plantarum AS21 and application thereof in preventing ulcerative colitis | |
TWI451871B (en) | Anti-inflammatory and anti-vaginitis food composition and pharmaceutical composition containing lactobacillus | |
JP3995733B2 (en) | Immunostimulatory composition | |
TWI666316B (en) | Lactic acid bacteria composition capable of preventing and treating bacterial vaginitis | |
AU2021106148A4 (en) | Application of Lactobacillus salivarius in Protecting Oral Health | |
CN116286486A (en) | Lactobacillus crispatus for relieving various vaginitis based on host immune regulation | |
CN114917208A (en) | Application of white spirit in preparing medicine for improving intestinal barrier function and intestinal flora |